Guardant Health, Inc.

DB:5GH Stock Report

Market Cap: €5.6b

Guardant Health Valuation

Is 5GH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5GH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€260.75
Fair Value
82.7% undervalued intrinsic discount
21
Number of Analysts

Below Fair Value: 5GH (€45.03) is trading below our estimate of fair value (€260.75)

Significantly Below Fair Value: 5GH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5GH?

Key metric: As 5GH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 5GH. This is calculated by dividing 5GH's market cap by their current revenue.
What is 5GH's PS Ratio?
PS Ratio8.7x
SalesUS$692.26m
Market CapUS$5.83b

Price to Sales Ratio vs Peers

How does 5GH's PS Ratio compare to its peers?

The above table shows the PS ratio for 5GH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
SYAB SYNLAB
0.9x4.4%€2.5b
FME Fresenius Medical Care
0.7x4.0%€13.7b
FRE Fresenius SE KGaA
0.9x3.6%€20.7b
V3V VITA 34
0.9x3.1%€72.2m
5GH Guardant Health
8.7x17.5%€5.8b

Price-To-Sales vs Peers: 5GH is expensive based on its Price-To-Sales Ratio (8.7x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does 5GH's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.08xn/aUS$3.80m
TLIK Arzneiwerk VIDA
0.06xn/aUS$3.44m
No more companies available in this PS range
5GH 8.7xIndustry Avg. 0.7xNo. of Companies3PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 5GH is expensive based on its Price-To-Sales Ratio (8.7x) compared to the European Healthcare industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is 5GH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5GH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.7x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: 5GH is expensive based on its Price-To-Sales Ratio (8.7x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5GH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€45.03
€43.29
-3.9%
14.9%€57.59€32.64n/a21
Jan ’26€28.95
€41.11
+42.0%
13.1%€57.10€32.35n/a20
Dec ’25€33.18
€39.83
+20.0%
13.6%€55.57€31.49n/a20
Nov ’25€19.91
€38.25
+92.1%
12.7%€45.97€29.42n/a20
Oct ’25€20.48
€38.28
+86.9%
14.1%€53.80€30.48n/a20
Sep ’25€23.31
€38.28
+64.2%
14.1%€53.80€30.48n/a20
Aug ’25€32.75
€36.12
+10.3%
17.1%€46.20€25.87n/a20
Jul ’25€26.75
€34.96
+30.7%
18.7%€43.87€26.14n/a20
Jun ’25€25.48
€34.66
+36.0%
19.9%€43.57€25.96n/a18
May ’25€16.89
€36.27
+114.8%
21.3%€46.64€25.18n/a18
Apr ’25€16.50
€37.76
+128.9%
20.7%€49.60€24.80n/a18
Mar ’25€17.50
€38.25
+118.6%
19.4%€49.77€24.88n/a18
Feb ’25€20.20
€42.68
+111.3%
18.5%€55.40€24.93n/a18
Jan ’25€25.00
€43.02
+72.1%
18.9%€58.30€24.60€28.9518
Dec ’24€23.00
€45.06
+95.9%
18.8%€59.80€25.23€33.1818
Nov ’24€24.40
€47.93
+96.4%
18.1%€69.87€32.10€19.9117
Oct ’24€28.40
€50.45
+77.6%
17.6%€70.44€32.36€20.4817
Sep ’24€36.00
€49.22
+36.7%
15.0%€67.52€36.50€23.3117
Aug ’24€35.40
€47.54
+34.3%
20.2%€66.52€26.97€32.7517
Jul ’24€33.40
€49.13
+47.1%
20.3%€68.98€27.97€26.7517
Jun ’24€27.40
€49.13
+79.3%
20.3%€68.98€27.97€25.4817
May ’24€20.80
€50.98
+145.1%
25.1%€82.70€31.01€16.8916
Apr ’24€20.93
€50.98
+143.7%
25.1%€82.70€31.01€16.5016
Mar ’24€28.87
€53.91
+86.7%
20.1%€83.42€34.12€17.5016
Feb ’24€28.57
€61.89
+116.7%
19.0%€83.63€34.21€20.2016
Jan ’24€25.05
€65.47
+161.4%
16.1%€84.91€47.17€25.0015
Analyst Price Target
Consensus Narrative from 21 Analysts
€41.78
Fair Value
7.8% overvalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 06:52
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guardant Health, Inc. is covered by 31 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Michael RyskinBofA Global Research
Derik de BruinBofA Global Research